Valuation: Gan & Lee Pharmaceuticals.

Capitalization 37.14B 5.25B 4.51B 4.22B 3.94B 7.33B 472B 7.95B 49.49B 19.09B 223B 19.71B 19.29B 815B P/E ratio 2025 *
33.7x
P/E ratio 2026 * 25.9x
Enterprise value 35.8B 5.06B 4.35B 4.07B 3.8B 7.07B 455B 7.66B 47.7B 18.4B 215B 19B 18.59B 785B EV / Sales 2025 *
8.53x
EV / Sales 2026 * 6.78x
Free-Float
50.32%
Yield 2025 *
0.29%
Yield 2026 * 0.38%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.73%
1 week-1.55%
Current month-1.99%
1 month-6.59%
3 months-19.49%
6 months+9.03%
Current year+41.50%
More quotes
1 week 61.5
Extreme 61.5
64.14
1 month 60.6
Extreme 60.6
68.4
Current year 40.4
Extreme 40.4
82.25
1 year 40.4
Extreme 40.4
82.25
3 years 32.03
Extreme 32.03
82.25
5 years 30.53
Extreme 30.53
181.28
10 years 30.53
Extreme 30.53
204.41
More quotes
Manager TitleAgeSince
Chief Executive Officer 48 19/07/2020
Director of Finance/CFO 46 19/07/2020
Corporate Officer/Principal 45 31/12/2018
Director TitleAgeSince
Chairman 77 16/06/1998
Director/Board Member 48 31/12/2009
Chairman 47 09/09/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.73%-1.55%+34.28%+80.50% 5.22B
-0.12%-7.88%-3.57%-5.69% 74.25B
-1.14%-1.42%-35.18%-38.82% 58.08B
+0.04%+0.88%+27.34%+224.01% 53.14B
+1.57%+68.00%+68.00%+68.00% 52.28B
+0.68%+0.02%+13.14%-39.12% 26.52B
+1.91%-1.42%+146.18%+237.12% 20.21B
-1.02%-4.91%+39.47%+20.85% 19.93B
-0.57%+0.19%+59.69%+1,310.33% 19.06B
+0.82%+4.24%+181.26%+689.44% 14.29B
Average +0.29%-1.18%+53.06%+254.66% 34.3B
Weighted average by Cap. +0.15%-1.42%+31.19%+152.21%
See all sector performances

Financials

2025 *2026 *
Net sales 4.2B 593M 510M 477M 445M 828M 53.27B 898M 5.59B 2.16B 25.23B 2.23B 2.18B 92.02B 5.18B 733M 629M 589M 550M 1.02B 65.8B 1.11B 6.9B 2.66B 31.16B 2.75B 2.69B 114B
Net income 1.1B 156M 134M 125M 117M 217M 13.98B 236M 1.47B 566M 6.62B 584M 572M 24.15B 1.45B 204M 176M 164M 153M 285M 18.36B 309M 1.93B 743M 8.69B 767M 751M 31.71B
Net Debt -1.34B -190M -163M -152M -142M -265M -17.03B -287M -1.79B -689M -8.06B -712M -696M -29.41B -2.01B -285M -245M -229M -214M -397M -25.56B -431M -2.68B -1.03B -12.11B -1.07B -1.05B -44.15B
More financial data * Estimated data
Logo Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
Employees
5,245
More about the company
Date Price Change Volume
04/12/25 62.40 ¥ +0.73% 4,066,877
03/12/25 61.95 ¥ -0.56% 5,402,340
02/12/25 62.30 ¥ -2.67% 5,791,646
01/12/25 64.01 ¥ +0.53% 4,669,415
28/11/25 63.67 ¥ +1.02% 4,605,932

End-of-day quote Shanghai S.E., December 03, 2025

More quotes
Trader
Investor
Global
Quality
ESG MSCI
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
62.40CNY
Average target price
74.50CNY
Spread / Average Target
+19.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603087 Stock